- Advertisement -
- Advertisement -

Rhenman & Partners Boosts Biopharma Expertise

Report: Systematic Strategies

- Advertisement -

Stockholm (HedgeNordic) – Rhenman & Partners is expanding its five-person investment team with the hiring of Amennai Beyeen as a biopharma analyst. He joins from global healthcare company Novartis.

“We are very happy to welcome Amennai to Rhenman & Partners,” says Henrik Rhenman, co-founder and CIO at Rhenman & Partners. “Amennai’s strong background and competence from the world of research, and his experience of pharmaceutical companies where he has been able to closely follow processes from idea to finished product make him a very good addition to our investment team.”

“We are very happy to welcome Amennai to Rhenman & Partners.”

Amennai Beyeen has worked for about 12 years at Novartis, focusing on the development and launch of new drugs. He also holds a doctorate in neuroimmunology from Karolinska Institutet in Stockholm. Beyeen will join the five-person investment team running the healthcare-focused equity hedge fund Rhenman Healthcare Equity L/S. He will have a particular focus on biopharma companies and the development of new drugs and treatments.

“It is very exciting to start at Rhenman & Partners,” Amennai Beyeen comments on joining the Swedish healthcare-focused asset manager. “I am extremely impressed by the team’s deep knowledge of the healthcare sector as well as the fund’s versatile investment process, which is reflected in its strong results over the years,” he continues. “I look forward to joining this competent team and contributing with my experience from the life science sector.”

Rhenman & Partners Asset Management has been running its long-biased equity hedge fund with an exclusive focus on healthcare since mid-2009, delivering an annualized return of 17.3 percent through November 2022. The fund’s main share class (IC1 EUR) edged down 1.6 percent in the first 11 months of this year. Rhenman Healthcare Equity L/S oversees €923 million in assets under management.

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Eugeniu Guzun
Eugeniu Guzun
Eugeniu Guzun serves as a data analyst responsible for maintaining and gatekeeping the Nordic Hedge Index, and as a journalist covering the Nordic hedge fund industry for HedgeNordic. Eugeniu completed his Master’s degree at the Stockholm School of Economics in 2018. Write to Eugeniu Guzun at eugene@hedgenordic.com

Latest Articles

Ridge Capital Expands Team After Hitting €100 Million Milestone

Stockholm (HedgeNordic) – With its unconventional high-yield bond strategy now exceeding €100 million in assets under management, Ridge Capital is expanding its portfolio management...

“7 Years, Niller, Then You Know a Thing or Two”

Stockholm (HedgeNordic) – There is a Danish saying that goes, “7 years, Niller, then you know a thing or two,” suggesting that seven years...

Brobacke Gains 7.6% in Early July, Predicts Continued Bull Market

Stockholm (HedgeNordic) – After a relatively flat first half of 2024, marked by noticeable month-over-month volatility, discretionary macro fund Brobacke Global Allokering advanced 7.6...

Kristofer Barrett Back to Managing Tech Fund

Stockholm (HedgeNordic) – Kristofer Barrett, the former portfolio manager of the multi-billion-dollar Swedbank Robur Technology fund, has returned to managing a technology-focused equity fund....

Tidan’s Resurgence Amid Markets Needing a Touch of Magic

Stockholm (HedgeNordic) – In late 2021, Michael Falken and his team at Tidan Capital launched a hedge fund employing a capital structure relative value...

The Value of Short Selling for Symmetry

Stockholm (HedgeNordic) – Stock-picking hedge fund Symmetry Invest has achieved a net-of-fees annualized return of 18 percent since its inception just over 11 years...

Allocator Interviews

In-Depth: High Yield

Voices

Request for Proposal

- Advertisement -